Biomarkers Predictive of Metabolic Syndrome and Cardiovascular Disease in Childhood Cancer Survivors
- PMID: 35743665
- PMCID: PMC9225298
- DOI: 10.3390/jpm12060880
Biomarkers Predictive of Metabolic Syndrome and Cardiovascular Disease in Childhood Cancer Survivors
Abstract
The improvement in childhood cancer treatments resulted in a marked improvement in the survival of pediatric cancer patients. However, as survival increased, it was also possible to observe the long-term side effects of cancer therapies. Among these, metabolic syndrome is one of the most frequent long-term side effects, and causes high mortality and morbidity. Consequently, it is necessary to identify strategies that allow for early diagnosis. In this review, the pathogenetic mechanisms of metabolic syndrome and the potential new biomarkers that can facilitate its diagnosis in survivors of pediatric tumors are analyzed.
Keywords: cancer survivors; cardiovascular disease; chemotherapy toxicity; childhood cancer; metabolic syndrome; obesity; radiotherapy toxicity.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Gatta G., Botta L., Rossi S., Aareleid T., Bielska-Lasota M., Clavel J., Dimitrova N., Jakab Z., Kaatsch P., Lacour B., et al. Childhood Cancer Survival in Europe 1999–2007: Results of EUROCARE-5—A Population-Based Study. Lancet Oncol. 2014;15:35–47. doi: 10.1016/S1470-2045(13)70548-5. - DOI - PubMed
-
- Vassal G., Schrappe M., Pritchard-Jones K., Arnold F., Basset L., Biondi A., Bode G., Eggert A., Hjorth L., Kamerić L., et al. The SIOPE Strategic Plan: A European Cancer Plan for Children and Adolescents. J. Cancer Policy. 2016;8:17–32. doi: 10.1016/j.jcpo.2016.03.007. - DOI
Publication types
LinkOut - more resources
Full Text Sources
